全球抗體熱門創造和發現市場 - 分析和預測（2023-2032）

全球抗體命中生成和發現市場規模是由慢性病的增加、抗體工程的進步以及研發投資的增加所推動的。

此外，個人化醫療需求的成長和生物製藥產業的擴張也促進了市場的良性循環。

該報告考察了全球抗體命中生成和發現市場，並提供了市場概述，包括按應用、技術、抗體類型、地區和進入市場的公司概況分類的趨勢。

目錄

執行摘要

調查範圍

調查方法

第1章 市場

• 全球市場展望
• 產品定義
• 涵蓋與排除標準
• 主要發現
• 先決條件和限制
• 世界市場情景
• 產業展望
• 主要趨勢
• 專利分析
• 產品基準評效
• COVID-19 對全球抗體命中生成和發現市場的影響
• 對市場規模的影響
• 市場進入障礙與機遇
• 業務動態
• 影響分析

第2章 全球抗體創造與發現市場（按技術）

• 機會評估
• 成長佔有率矩陣

第3章 全球抗體創造與發現市場（按抗體類型）

• 機會評估
• 成長佔有率矩陣

第4章 全球抗體創造與發現市場（依應用）

• 機會評估
• 成長佔有率矩陣

第5章 區域

• 北美抗體進入創造和發現市場
• 歐洲抗體進入創造和發現市場
• 亞太地區抗體創造與發現市場
• 拉丁美洲抗體衝擊創造與發現市場
• 抗體衝擊其他地區的創造和發現市場

第6章市場

• 競爭基準化分析和公司簡介
• 競爭形勢
  • 關鍵策略和發展
• 公司簡介
  • F. Hoffmann-La Roche Ltd.
  • AbbVie
  • Pfizer
  • AstraZeneca
  • Novartis
  • Eli Lilly
  • WuXi AppTec
  • Charles River Laboratories
  • Syngenta
  • BioLegend
  • Creative Biolabs
  • Eurofins CDMO
  • AbCellera
  • MorphoSys
  • Evelo Biosciences
  • Icos Therapeutics
  • Argenx
  • Kymab
  • Alnylam Pharmaceuticals
  • SAb Biotherapeutics
  • 其他公司

The Global Antibody Hit Generation and Screening Market report offers a detailed and comprehensive analysis of the industry, providing valuable insights into market trends, growth drivers, challenges, and future opportunities. The report covers key segments, competitive landscape, and emerging technologies, offering stakeholders a holistic view of the global market.

The study identifies and analyzes the primary drivers influencing market growth. Factors such as the increasing prevalence of chronic diseases, advancements in antibody engineering, and rising investments in research and development are explored. Additionally, the growing demand for personalized medicine and the expanding biopharmaceutical industry contribute to the positive trajectory of the market.

Market Segmentation:

Segmentation 1: by Application

• Cancer
• Autoimmune diseases
• Infectious diseases

Segmentation 2: by Technologies

• Hit Generation
• Phage display
• Yeast display
• Ribosome display
• B-cell hybridoma technology
• Computational tools
• Screening

Segmentation 3: by Antibody Type

• Humanized Antibody
• Human Antibody
• Chimeric Antibody
• Murine Antibody

Segmentation 4: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World

Some prominent players established in this market are:

• Creative Biolabs
• F. Hoffmann-La Roche Ltd.
• WuXi AppTec
• Icos Therapeutics

Key Questions Answered:

• What are the major market drivers, challenges and opportunities in the global antibody hit generation and screening market?
• How the antibody hit generation and screening market evolves and what did is its scope in the future?
• How will each segment of the global antibody hit generation and screening market grow during the forecast period?
• How will the industry evolve during the forecast period?
• What are the key developmental strategies implemented by the key players to stand out in this market?

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Market

• 1.1. Global Market Outlook
• 1.2. Product Definition
• 1.3. Inclusion and Exclusion Criteria
• 1.4. Key Findings
• 1.5. Assumptions and Limitations
• 1.6. Global Market Scenario
  • 1.6.1. Realistic Scenario
  • 1.6.2. Optimistic Scenario
  • 1.6.3. Pessimistic Scenario
• 1.7. Industry Outlook
• 1.8. Key Trends
• 1.9. Patent Analysis
  • 1.9.1. Awaited Technological Developments
  • 1.9.2. Patent Filing Trend (by Country/Cluster)
  • 1.9.3. Patent Filing Trend (by Year)
• 1.10. Product Benchmarking
• 1.11. Impact of COVID-19 on Global Antibody Hit Generation and Screening Market
• 1.12. Impact on Market Size
  • 1.12.1. Pre-COVID-19 Phase
  • 1.12.2. During-COVID-19 Phase
  • 1.12.3. Post-COVID-19 Phase
• 1.13. Market Entry Barriers and Opportunities
• 1.14. Business Dynamics
• 1.15. Impact Analysis
  • 1.15.1. Business Drivers
  • 1.15.2. Business Restraints
  • 1.15.3. Business Opportunities

2. Global Antibody Hit Generation and Screening Market (by Technologies)

• 2.1. Opportunity Assessment
• 2.2. Growth Share Matrix
  • 2.2.1. Hit Generation
  • 2.2.2. Phage display
  • 2.2.3. Yeast display
  • 2.2.4. Ribosome display
  • 2.2.5. B-cell hybridoma technology
  • 2.2.6. Computational tools
  • 2.2.7. Screening

3. Global Antibody Hit Generation and Screening Market (by Antibody Type)

• 3.1. Opportunity Assessment
• 3.2. Growth Share Matrix
  • 3.2.1. Humanized Antibody
  • 3.2.2. Human Antibody
  • 3.2.3. Chimeric Antibody
  • 3.2.4. Murine Antibody

4. Global Antibody Hit Generation and Screening Market (by Applications)

• 4.1. Opportunity Assessment
• 4.2. Growth Share Matrix
  • 4.2.1. Cancer
  • 4.2.2. Autoimmune diseases
  • 4.2.3. Infectious diseases

5. Region

• 5.1. North America Antibody Hit Generation and Screening Market
• 5.2. Key Findings and Opportunity Assessment
• 5.3. Regulatory Framework
• 5.4. Market Dynamics
  • 5.4.1. Impact Analysis
• 5.5. Sizing and Forecast Analysis
  • 5.5.1. North America Antibody Hit Generation and Screening Market (by Technologies)
  • 5.5.2. North America Antibody Hit Generation and Screening Market (by Country)
    • 5.5.2.1.1. U.S.
    • 5.5.2.1.2. Canada
• 5.6. Europe Antibody Hit Generation and Screening Market
• 5.7. Key Findings and Opportunity Assessment
• 5.8. Regulatory Framework
• 5.9. Market Dynamics
  • 5.9.1. Impact Analysis
• 5.10. Sizing and Forecast Analysis
  • 5.10.1. Europe Antibody Hit Generation and Screening Market (by Technologies)
  • 5.10.2. Europe Antibody Hit Generation and Screening Market (by Country)
    • 5.10.2.1.1. Germany
    • 5.10.2.1.2. France
    • 5.10.2.1.3. U.K.
    • 5.10.2.1.4. Italy
    • 5.10.2.1.5. Spain
    • 5.10.2.1.6. Rest-of-Europe
• 5.11. Asia-Pacific Antibody Hit Generation and Screening Market
• 5.12. Key Findings and Opportunity Assessment
• 5.13. Regulatory Framework
• 5.14. Market Dynamics
  • 5.14.1. Impact Analysis
• 5.15. Sizing and Forecast Analysis
  • 5.15.1. Asia-Pacific Antibody Hit Generation and Screening Market (by Technologies)
  • 5.15.2. Asia-Pacific Antibody Hit Generation and Screening Market (by Country)
    • 5.15.2.1.1. Japan
    • 5.15.2.1.2. China
    • 5.15.2.1.3. Australia
    • 5.15.2.1.4. India
    • 5.15.2.1.5. South Korea
    • 5.15.2.1.6. Rest-of-Asia-Pacific
• 5.16. Latin America Antibody Hit Generation and Screening Market
• 5.17. Key Findings and Opportunity Assessment
• 5.18. Regulatory Framework
• 5.19. Market Dynamics
  • 5.19.1. Impact Analysis
• 5.20. Sizing and Forecast Analysis
  • 5.20.1. Latin America Antibody Hit Generation and Screening Market (by Technologies)
  • 5.20.2. Latin America Antibody Hit Generation and Screening Market (by Country)
    • 5.20.2.1.1. Brazil
    • 5.20.2.1.2. Mexico
    • 5.20.2.1.3. Rest-of-Latin America
• 5.21. Rest-of-the-World Antibody Hit Generation and Screening Market
• 5.22. Key Findings and Opportunity Assessment
• 5.23. Regulatory Framework
• 5.24. Market Dynamics
  • 5.24.1. Impact Analysis
• 5.25. Sizing and Forecast Analysis
  • 5.25.1. Rest-of-the-World Antibody Hit Generation and Screening Market (by Technologies)

6. Markets

• 6.1. Competitive Benchmarking and Company Profiles
• 6.2. Competitive Landscape
  • 6.2.1. Key Strategies and Developments
    • 6.2.1.1.1. Partnerships, Alliances, and Business Expansion
    • 6.2.1.1.2. Funding Activities
    • 6.2.1.1.3. New Offerings
    • 6.2.1.1.4. Mergers and Acquisitions
    • 6.2.1.1.5. Regulatory and Legal Activities
• 6.3. Company Profiles
  • 6.3.1. F. Hoffmann-La Roche Ltd.
  • 6.3.2. Company Overview
  • 6.3.3. Product Portfolio
  • 6.3.4. Financials
  • 6.3.5. Recent Developments
  • 6.3.6. Analyst Perspective
  • 6.3.7. AbbVie
  • 6.3.8. Pfizer
  • 6.3.9. AstraZeneca
  • 6.3.10. Novartis
  • 6.3.11. Eli Lilly
  • 6.3.12. WuXi AppTec
  • 6.3.13. Charles River Laboratories
  • 6.3.14. Syngenta
  • 6.3.15. BioLegend
  • 6.3.16. Creative Biolabs
  • 6.3.17. Eurofins CDMO
  • 6.3.18. AbCellera
  • 6.3.19. MorphoSys
  • 6.3.20. Evelo Biosciences
  • 6.3.21. Icos Therapeutics
  • 6.3.22. Argenx
  • 6.3.23. Kymab
  • 6.3.24. Alnylam Pharmaceuticals
  • 6.3.25. SAb Biotherapeutics
  • 6.3.26. Other Companies

* Financials are provided for the public companies only